Primary Objectives:
Secondary Objectives:
For RDE-confirmation in the escalation part: patients with selected advanced solid tumors, i.e.,
For the expansion Part:
1) Patients must have the following FGFR genetic alterations based on central laboratory tests or existing test reports of tumor tissue and/or blood:
2) Patients must have at least one measurable target lesion according to RECIST 1.1
3) Previous FGFR inhibitors treated and progressed cohort in UC or iCCA patients: received treatment with FGFR inhibitors and experienced disease progression/recurrence during or after FGFR inhibitors treatment